Jump Financial LLC bought a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,739 shares of the company's stock, valued at approximately $453,000.
Several other hedge funds have also recently added to or reduced their stakes in ALKS. Barclays PLC raised its position in Alkermes by 108.8% in the third quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after acquiring an additional 220,893 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Alkermes in the third quarter worth about $582,000. Tidal Investments LLC bought a new stake in Alkermes in the third quarter worth about $1,098,000. Franklin Resources Inc. raised its position in Alkermes by 2.5% in the third quarter. Franklin Resources Inc. now owns 120,006 shares of the company's stock worth $3,486,000 after acquiring an additional 2,903 shares in the last quarter. Finally, Diversified Trust Co raised its position in Alkermes by 11.5% in the fourth quarter. Diversified Trust Co now owns 42,509 shares of the company's stock worth $1,223,000 after acquiring an additional 4,378 shares in the last quarter. Institutional investors own 95.21% of the company's stock.
Analyst Upgrades and Downgrades
ALKS has been the topic of a number of analyst reports. StockNews.com raised Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. The Goldman Sachs Group lifted their target price on Alkermes from $30.00 to $32.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Deutsche Bank Aktiengesellschaft lifted their target price on Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. HC Wainwright reaffirmed a "neutral" rating and set a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. Finally, Royal Bank of Canada reaffirmed an "underperform" rating on shares of Alkermes in a research note on Monday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.08.
Get Our Latest Analysis on ALKS
Insider Transactions at Alkermes
In related news, EVP Craig C. Hopkinson sold 100,918 shares of the firm's stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total value of $3,234,421.90. Following the completion of the transaction, the executive vice president now directly owns 44,290 shares of the company's stock, valued at $1,419,494.50. This trade represents a 69.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.40% of the company's stock.
Alkermes Price Performance
Shares of ALKS stock remained flat at $28.77 during trading hours on Wednesday. The stock had a trading volume of 2,422,948 shares, compared to its average volume of 1,759,969. Alkermes plc has a one year low of $22.90 and a one year high of $36.45. The company has a market capitalization of $4.74 billion, a PE ratio of 13.26, a P/E/G ratio of 2.20 and a beta of 0.39. The business's fifty day simple moving average is $31.49 and its two-hundred day simple moving average is $30.40.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities research analysts forecast that Alkermes plc will post 1.31 earnings per share for the current fiscal year.
Alkermes Company Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
